Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC secretory peptide cocktail is a combination of mesenchymal stromal cell (MSC)-derived secretory molecules, specifically consisting of human recombinant annexin A1 (ANXA1), stromal cell-derived factor-1 (SDF-1/CXCL12), and complement component C3 (C3a). Developed by researchers at King's College London, this cocktail is designed to improve the functional survival and quality of human islets and stem cell-derived islets (SC-islets) for transplantation therapy in type 1 diabetes. Pretreatment with the cocktail protects islets against cytokine-induced apoptosis, increases ATP-coupled respiration, and enhances glucose-stimulated insulin secretion (GSIS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSC secretory peptide cocktail.